Virtual Challenging Case Clinic: B-Cell Lymphomas Transformed Lymphoma
Release Date: June 18, 2020
Expiration Date: June 18, 2021
This activity is for clinicians who treat patients with indolent and aggressive B-cell lymphomas: hematologists, medical oncologists, oncology nurses, nurse practitioners, oncology pharmacists, and other healthcare professionals.
After completing this activity, participants should be better able to:
- Evaluate the best available evidence regarding treatment for transformed lymphoma
- Assess the implications of emerging clinical trial data regarding transformed lymphoma therapy approaches
- Develop strategies to address complicated transformed lymphoma cases
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
Method of Participation
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
All disclosed conflicts of interest have been resolved by independent content review.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
All faculty and planning committee members have no conflicts to disclose with the exception of the following:
John P. Leonard, MD
Senior Associate Dean for Innovation and Initiatives
Executive Vice Chair, Weill Department of Medicine
Richard T. Silver Distinguished Professor of Hematology & Medical Oncology
Weill Cornell Medical College
New York, New York
Consulting Fees: ADC Therapeutics, AstraZeneca, Bayer, Bristol-Myers Squibb Company, Epizyme, a Kite Gilead Company, MEI Pharma, Miltenyi Biotec, Regeneron, Roche/Genentech, Sutro Biopharma
Andrew Zelenetz, MD, PhD
Professor of Medicine
Weill Cornell Medical College
Medical Director, Quality Informatics
Memorial Sloan Kettering Cancer Center
New York, New York
Consulting Fees: AbbVie, Adaptive Biotech, Amgen, AstraZeneca, Celgene Corporation, Gilead Sciences, Inc., Janssen, Novartis, Roche/Genentech
DMC Chair: BeiGene
Grants/Research Support: BeiGene, Gilead Sciences, Inc., MEI Pharma, Roche
Educational grant support provided by AstraZeneca, Bristol Myers Squibb, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.